Does Humana Cover NMN/NR (Nicotinamide Mononucleotide/Riboside)?

Why Humana Does Not Cover NMN or NR

Humana builds its formularies around FDA-approved medications. NMN and NR are both NAD+ precursors sold as dietary supplements, and neither compound has received FDA approval as a prescription drug. That single fact drives the coverage decision across every Humana plan type.

The FDA Classification Problem

Nicotinamide riboside (sold as Niagen by ChromaDex) is marketed under the Dietary Supplement Health and Education Act (DSHEA) of 1994. NMN's status is more complicated. In October 2022, the FDA ruled that NMN could not be sold as a dietary supplement because it was being investigated as a new drug candidate (IND) by Metro International Biotech. That ruling triggered market confusion, though many retailers continued selling NMN products. As of early 2026, NMN remains in regulatory limbo: no FDA drug approval exists, and the supplement pathway is disputed 1.

How Formulary Exclusion Works

Humana's pharmacy and therapeutics committee reviews compounds that carry an FDA-assigned National Drug Code (NDC) and an approved indication. Supplements lack both. Because NMN and NR do not appear in the FDA's Orange Book or Purple Book, they cannot be assigned a formulary tier. This applies equally to Humana Commercial PPO/HMO plans and Humana Medicare Advantage (MA) Part D plans 2.

No prior authorization form, step therapy protocol, or quantity limit applies. The product simply does not exist within Humana's pharmacy benefit system.

What the Clinical Evidence Actually Shows

The interest in NMN and NR stems from preclinical NAD+ research, but human trial data remain limited in size and duration. Understanding where the science stands helps explain why insurers have no clinical basis for coverage.

The Yoshino 2021 Trial

The most frequently cited NMN study is Yoshino et al., published in Science in 2021. This randomized, placebo-controlled trial enrolled 25 postmenopausal women with prediabetes and obesity, giving 250 mg/day of NMN for 10 weeks. The NMN group showed a 25% improvement in skeletal muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. Blood NAD+ metabolites increased. Body weight did not change significantly 3.

That sample size (N=25) and short duration fall far below the evidence threshold insurers require. By comparison, metformin's approval rested on trials enrolling thousands of patients over years.

Nicotinamide Riboside Data

The CHROMADEX-sponsored trial by Martens et al. (2018) tested NR at 1,000 mg/day in 24 lean, healthy older adults for 6 weeks. NR raised circulating NAD+ by approximately 60% and produced a trend toward lower systolic blood pressure (reduction of ~3.4 mmHg in the crossover analysis), though the study was not powered for cardiovascular endpoints 4.

A larger trial by Elhassan et al. (2019) in 12 older men confirmed NAD+ elevation with NR supplementation but found no change in skeletal muscle mitochondrial function over 21 days 5.

Why This Matters for Coverage

Insurance formulary inclusion requires three conditions that NMN/NR currently fail to meet:

1. FDA drug approval with a labeled indication. Neither compound has one.
2. Phase III efficacy data showing clinically meaningful outcomes (not just biomarker changes). No completed Phase III trial exists for either NMN or NR.
3. Pharmacoeconomic review demonstrating cost-effectiveness versus existing therapies. Without an approved indication, this analysis cannot proceed.

Until at least one of these milestones is reached, no major U.S. Insurer (Humana, UnitedHealthcare, Aetna, Cigna, or BCBS) is expected to add NMN or NR to a formulary.

Humana Medicare Advantage and NMN/NR

Medicare Part D carries an additional exclusion layer. The Social Security Act, Section 1860D-2(e)(2)(A), explicitly excludes "vitamins and minerals" and products used for "weight loss" or "cosmetic purposes" from Part D coverage. CMS has interpreted this broadly to include dietary supplements, even those with plausible metabolic effects 6.

Can a Part D Exception Override This?

Technically, a Humana MA plan member can request a coverage determination or exception. The process involves submitting a request to Humana's Part D coverage determination unit, including a prescriber's supporting statement explaining medical necessity.

In practice, this pathway fails for NMN/NR because:

• The product has no NDC in most pharmacy adjudication systems
• No FDA-approved indication exists to support "medical necessity"
• CMS audits plans that approve supplement coverage exceptions

The appeal would proceed from Humana's internal review to the Independent Review Entity (IRE), and for Medicare cases, to the Office of Medicare Hearings and Appeals (OMHA). Success rates for non-FDA-approved supplements at these levels are negligible.

How to Access NMN/NR Without Insurance Coverage

Since insurance is off the table for now, the practical question becomes: how do you get reliable NMN or NR at a reasonable price?

Retail Supplement Pricing

NR (as Niagen/Tru Niagen by ChromaDex) typically costs $40 to $50 per month at the standard 300 mg/day dose. NMN products range more widely, from $30 to $120 per month depending on brand, dose (250 mg to 1,000 mg/day), and purity testing.

Third-Party Testing Matters

Because supplements are not subject to FDA premarket approval, product quality varies significantly. Look for brands that provide certificates of analysis (COA) from independent labs such as NSF International, USP, or ConsumerLab. A 2022 analysis found that some NMN products contained less than 50% of labeled dose 7.

HSA and FSA Eligibility

Health savings accounts (HSAs) and flexible spending accounts (FSAs) generally do not cover dietary supplements unless a physician writes a letter of medical necessity for a diagnosed condition. The IRS defines eligible expenses under Section 213(d) of the Internal Revenue Code. A supplement recommended for general wellness or longevity does not qualify. If a physician diagnoses a specific condition (e.g., NAD+ deficiency documented by lab work) and prescribes NMN or NR as treatment, some HSA administrators will approve the expense. This is plan-specific and inconsistent.

Compounding Pharmacy Options

Some compounding pharmacies prepare NMN or NR in capsule or sublingual formulations. Compounded products may carry a pharmacy NDC, but this does not make them insurance-eligible. Compounded NMN typically costs $60 to $100 per month. HealthRX offers physician-supervised NAD+ precursor protocols that include lab monitoring of NAD+ metabolite levels.

What About Prescription NAD+ Therapies?

There is a distinction between OTC supplements (NMN, NR) and prescription NAD+ formulations. Some clinics offer intravenous NAD+ infusions, which are administered as compounded preparations and billed as medical procedures rather than pharmacy claims.

IV NAD+ Infusion Coverage

IV NAD+ infusions cost $250 to $1,000 per session. These are not covered by Humana under either the pharmacy or medical benefit. No CPT code specific to NAD+ infusion has been established, and clinics that bill these services typically use miscellaneous injection codes (e.g., 96365 for IV infusion) paired with unspecified diagnoses. Humana routinely denies these claims.

The Pipeline: NMN as an Investigational Drug

Metro International Biotech (now part of a larger development effort) filed an IND for MIB-626, a pharmaceutical-grade NMN formulation. A Phase II trial (NCT05511025) evaluated MIB-626 in adults with obesity. If this or a similar NMN drug candidate completes Phase III trials and receives FDA approval, the coverage picture would change entirely. An FDA-approved NMN drug with a labeled indication would be eligible for formulary review by Humana and all other insurers 8.

That timeline, if it proceeds at all, likely extends to 2028 or beyond.

Steps to Take If Your Humana Claim Is Denied

Even though coverage is unlikely, some members receive denials after a provider submits a claim. Here is the appeal pathway, presented for completeness.

Internal Appeal

File a written appeal within 180 days of the denial (60 days for Medicare Advantage). Include the prescriber's letter of medical necessity, any supporting lab results (e.g., intracellular NAD+ levels), and citations to peer-reviewed literature. Humana must respond within 30 days for standard commercial appeals or 7 days for expedited MA appeals.

External Review

If the internal appeal is denied, commercial plan members may request an external review through their state insurance department. Medicare Advantage members proceed to the IRE (currently Maximus Federal Services), which reviews the case independently. The IRE decision is binding on Humana unless either party appeals to OMHA.

Realistic Expectations

The Humana denial is almost certainly correct under current policy. An appeal consumes time and administrative effort. For a product costing $40 to $80 per month, most members find that self-pay is more practical than pursuing a multi-step appeal process with a very low probability of success.

Comparing NAD+ Precursors by Cost and Evidence

| Compound | Monthly Cost | NAD+ Elevation | Human Trial Evidence | Insurance Coverage | |---|---|---|---|---| | NMN (supplement) | $30 to $120 | Yes (dose-dependent) | Small RCTs (N < 50) | None | | NR (Tru Niagen) | $40 to $50 | Yes (~60% increase) | Small RCTs (N < 30) | None | | Niacin (vitamin B3) | $5 to $10 | Modest | Extensive (AIM-HIGH, HPS2-THRIVE) | OTC, no Rx needed | | IV NAD+ infusion | $250 to $1,000/session | Yes (transient) | Case series only | None | | MIB-626 (investigational) | N/A (clinical trial) | Yes | Phase II ongoing | Future possibility |

Niacin raises NAD+ through a different biosynthetic pathway and costs a fraction of NMN or NR. Its flushing side effect limits tolerability for some users, though extended-release formulations reduce this. For patients whose primary goal is NAD+ repletion, niacin remains the most cost-effective option 9.